BUSINESS DEVELOPMENT & EARLY R&D
What is the Clinical Innovation offered by your target product profile and how does that translate to peak share?
When deciding next steps in an early-stage program or business development opportunity, it is crucial to have a data-driven assessment of how the asset lines up against current therapies. Our framework provides an in-depth comparison that helps drive R&D decisions and give insight into peak share potential.
Disease Target Assessment
Disease Target Assessment (DTA) is a modeling framework that provides a rigorous and objective measure of the clinical improvement a TPP offers over the standard of care in a specified patient population. We have shown that our measure of clinical improvement (Clinical Innovation) drives peak share based on an extensive analysis of numerous historical drug launches.
DTA models predict peak patient-share for any modeled TPP and can instantly be updated when new data emerges. Given this dynamic nature, we are able to add on our “Competition Module” functionality when the asset reaches late-stage development, which forecasts the patient share over time of a drug and all its relevant competitors.
Interested in share over time? Look into our Competition Module.
Market access
Our market access analytics can be used for both early and late stage assets. We compare the clinical benefit of the drug to its cost, and benchmark those results to a historical data set of launched drugs to identify appropriate analogs. Our clinical benefit vs. cost metric is strongly predictive of the pricing and market access outlook for new agents.
Oncology TPP Predictor
Equinox Group has developed a proprietary oncology-focused endpoints database, spanning over 30,000 drug regimens. It has the analytical power to project likely OS outcomes for a given TPP with known PFS, based on drug characteristics such as tumor type and mechanism.
